Specialty cancer diagnostics firm Precipio Q3 revenue rises 30% driven by new customers

Reuters
2025/11/15
Specialty cancer diagnostics firm Precipio Q3 revenue rises 30% driven by new customers 

Overview

  • Precipio Q3 2025 revenue grows 30% YoY to $6.8 mln

  • Adjusted EBITDA turns positive in Q3 2025, improving by over $500K from Q2

  • Company generates $285K cash from operations in Q3 2025

Outlook

  • Company anticipates gross margins to increase towards 50%

Result Drivers

  • PATHOLOGY SERVICES GROWTH - Revenue increased 20% due to new customer accounts in the pipeline

  • PRODUCT DIVISION EXPANSION - Revenue rose 16% from existing customers and new panel orders

  • OPERATIONAL EFFICIENCIES - Positive EBITDA and cash generation attributed to operational efficiencies and financial discipline

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

$6.80 mln

Press Release: ID:nGNX4zwyxv

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10